Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

63%

5 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

5(71.4%)

Phase 2

2(28.6%)

7Total

Phase 4(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07239570Phase 4Recruiting

A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease

Role: lead

NCT06906081Phase 2Recruiting

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Role: lead

NCT02040441Phase 2Completed

Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria

Role: lead

NCT02829177Phase 4Completed

Microalbuminuria and Allopurinol in Type 1 Diabetes

Role: lead

NCT02914691Phase 4Completed

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

Role: lead

NCT03509454Completed

PeRsOnalising Treatment Of Diabetic Nephropathy:

Role: lead

NCT01499108Phase 4Completed

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes

Role: lead

NCT01331317Phase 4Completed

Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy

Role: lead

All 8 trials loaded